Diffuse Large Cell Diffuse Lymphoma, Follicular Lymphoma
Conditions
Brief summary
The development of new diagnostic tools and targeted therapy have significantly improved the management of non-Hodgkin's malignant lymphomas and thus their long-term prognosis. However, in the study of improved patient management, survival is not the only measurable indicator and preservation of quality of life is an essential component. In addition, there is little existing data regarding the determinants of quality of life in patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) in the general population in France.
Interventions
OTHERQuestionnaires
QLQ-C30, SF-12, HADS, SARASON, EPICES, socio-professional data
OTHERCollection of clinical data and treatments
clinical data and treatments
Sponsors
Centre Hospitalier Universitaire Dijon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patients diagnosed with DLBCL or FL between January 1, 2010 and December 31, 2017, * Alive as of January 1, 2021, * Updated patient address.
Exclusion criteria
* Other forms of Hematologic Malignancies at diagnosis, * Minors. * Person subject to legal protection (curatorship, guardianship) * Person subject to a judicial safeguard measure * Pregnant, parturient or breastfeeding woman * Adults incapable of giving consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Generic Questionnaire SF-12 | At inclusion |
| Specific questionnaire QLQ-C30 | At inclusion |
Countries
France
Outcome results
None listed